Initiating Injectable Buprenorphine in People Hospitalized With Infections

作者：Nikhil Seval, Prerana Roth, Cynthia Frank, Angela Di Paola, Alain H. Litwin, Brent Vander Wyk, Victor Neirinckx, Esther Schlossberg, Patrick Lawson, Michelle Strong, Meredith Schade, Jonathan Nunez, Frances R. Levin, Kathleen T. Brady, Edward V. Nunes, Sandra A. Springer · 发表于：JAMA Network Open · 年份：2025 · DOI：10.1001/jamanetworkopen.2025.13000 · 被引用次数：4 · 研究领域：Opioid Use Disorder Treatment、HIV, Drug Use, Sexual Risk、Suicide and Self-Harm Studies

Importance: Hospitalizations are increasing in the US due to infections related to opioid use disorder (OUD); however, few patients have treatment with medications for OUD (MOUD) initiated. Injectable long-acting buprenorphine (LAB) could help improve MOUD receipt and infection treatment completion. Objective: To compare initiation of LAB combined with infectious disease (ID) management (ID-LAB) with treatment as usual (TAU) during inpatient medical hospitalization periods for improving receipt of MOUD at 12 weeks. Design, Setting, and Participants: The Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (COMMIT) trial was a multisite randomized clinical trial with enrollment from August 19, 2020, through October 31, 2023, at 3 US hospital systems in Connecticut, Pennsylvania, and South Carolina. Eligible participants were individuals hospitalized with a diagnosis of moderate to severe OUD according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) and concurrent infection. Intent-to-treat outcomes were assessed at the end of the 12-week intervention period. Interventions: Participants were randomized 1:1 to receive ID-LAB or TAU during treatment for infection in a hospital setting or early after discharge. All participants received a nurse care medical management intervention. Main Outcomes and Measures: The primary outcome was the proportion of patients who received any form of MOUD at 12 weeks after randomization...